COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

An Open Label, Multi-Center Phase IIIb Study Of Asciminib (ABL001) Monotherapy In Previously Treated Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With And Without T315I Mutation (AIM4CML)

Protocol No
NOVARTIS-CABL001AUS04-AIM4CML
Principal Investigator
Ehab Atallah
Phase
III
Summary
The purpose of the study is to look how well the treatment with Asciminib works in participants with CML-CP that were previously treated with other therapies, with or without T315I mutation.
Description
ABL001 in Previously Treated CML-CP With or Without T315I Mutation
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL